Success Metrics

Clinical Success Rate
80.0%

Based on 20 completed trials

Completion Rate
80%(20/25)
Active Trials
1(3%)
Results Posted
80%(16 trials)
Terminated
5(17%)

Phase Distribution

Ph phase_4
5
17%
Ph phase_3
11
38%
Ph phase_2
6
21%
Ph phase_1
7
24%

Phase Distribution

7

Early Stage

6

Mid Stage

16

Late Stage

Phase Distribution29 total trials
Phase 1Safety & dosage
7(24.1%)
Phase 2Efficacy & side effects
6(20.7%)
Phase 3Large-scale testing
11(37.9%)
Phase 4Post-market surveillance
5(17.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

71.4%

20 of 28 finished

Non-Completion Rate

28.6%

8 ended early

Currently Active

1

trials recruiting

Total Trials

29

all time

Status Distribution
Active(1)
Completed(20)
Terminated(8)

Detailed Status

Completed20
Terminated5
Withdrawn3
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
29
Active
1
Success Rate
80.0%
Most Advanced
Phase 4

Trials by Phase

Phase 17 (24.1%)
Phase 26 (20.7%)
Phase 311 (37.9%)
Phase 45 (17.2%)

Trials by Status

withdrawn310%
completed2069%
recruiting13%
terminated517%

Recent Activity

Clinical Trials (29)

Showing 20 of 29 trialsScroll for more
NCT05179876Phase 3

A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option

Recruiting
NCT02932410Phase 3

A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)

Completed
NCT05167825Phase 3

A Study of Macitentan in Japanese Pediatric Participants With Pulmonary Arterial Hypertension

Completed
NCT04271475Phase 3

A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension

Terminated
NCT01346930Phase 2

Safety and Tolerability Study of Macitentan in Patients With Idiopathic Pulmonary Fibrosis

Withdrawn
NCT03359291Phase 1

Clinical Study to Investigate the Effect of Macitentan on the Concentrations of Rosuvastatin in the Blood of Healthy Male Subjects

Completed
NCT03422328Phase 3

A Clinical Study to Investigate the Long-term Safety of the Drug Macitentan in Patients With Pulmonary Hypertension Who Were Previously Treated With Macitentan in Clinical Studies.

Completed
NCT04211272Phase 1

A 2-part Study to Investigate the Effect of Macitentan in Healthy Male Participants

Completed
NCT02112487Phase 3

Extension of the Psychometric Validation Study ORCHESTRA in Patients With PAH

Completed
NCT05392530Phase 1

A Study of Two Different Test Formulations Compared to the Reference Formulation of Macitentan in Healthy Adult Participants

Completed
NCT05433675Phase 1

A Study of Two Macitentan Formulations in Healthy Adult Participants

Completed
NCT00667823Phase 3

Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension

Completed
NCT04963439Phase 1

A Study of Two Macitentan Pediatric Formulations in Healthy Adult Participants

Completed
NCT02310672Phase 4

REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension

Completed
NCT02382016Phase 4

PORtopulmonary Hypertension Treatment wIth maCitentan - a randOmized Clinical Trial

Completed
NCT03153111Phase 2

A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease

Completed
NCT04235270Phase 1

A Study of Macitentan and Tadalafil as a Fixed Dose Combination and the Free Combination in Healthy Adult Participants

Completed
NCT05731492Phase 1

A Study of Macitentan in Children Below 2 Years of Age

Withdrawn
NCT02021292Phase 2

Clinical Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension

Completed
NCT02558231Phase 3

The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension

Completed

Drug Details

Intervention Type
DRUG
Total Trials
29